Related Experiment Videos
Oncogenes and glial tumors
1Centre for Research in Neuroscience, McGill University, Montreal, Canada.
Abstract:
Results of numerous studies indicate that both activation of dominant oncogenes and inactivation of tumor suppressor genes play important roles in the genesis and progression of human gliomas. Activation of the epidermal growth factor receptor (erbB1 oncogene) as the result of gene amplification or rearrangement is the best established example of a dominant oncogene involved in glioma development. There is also suggestive evidence for activation of the ros oncogene in gliomas, and activation of a variety of other dominant oncogenes may be operative in individual tumors. Deletion studies suggest that inactivation of tumor suppressor genes on chromosomes 17p (probably the p53 gene), 10, 9p and 22 also play roles in genesis and progression of human gliomas. Additional work remains to be done to identify other dominant oncogenes and tumor suppressor genes involved in gliomas, and to determine how these various factors interact to cause disease.
Insights
Activation of oncogenes and inactivation of tumor suppressor genes drive human glioma development. Key genes include epidermal growth factor receptor (EGFR) and p53, crucial for understanding glioma genesis and progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human gliomas arise from complex genetic alterations.
- Both oncogene activation and tumor suppressor gene inactivation are implicated in glioma genesis and progression.
Purpose of the Study:
- To review the roles of dominant oncogenes and tumor suppressor genes in human glioma development.
- To highlight key genetic factors involved in glioma genesis and progression.
Main Methods:
- Review of numerous studies on glioma genetics.
- Analysis of gene amplification, rearrangement, and deletion data.
- Identification of specific oncogenes and tumor suppressor genes.
Main Results:
- Epidermal growth factor receptor (EGFR) activation via gene amplification/rearrangement is a well-established oncogene in gliomas.
- Evidence suggests ros oncogene activation and other dominant oncogenes may be involved.
- Tumor suppressor gene inactivation on chromosomes 17p (likely p53), 10, 9p, and 22 is implicated in glioma development.
Conclusions:
- Genetic alterations, including oncogene activation and tumor suppressor gene inactivation, are fundamental to human glioma development.
- Further research is needed to identify all relevant genes and their interactions in gliomas.